Project Grant R01CA280279
- This Project Grant award of $704,206 was provided by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121). The grant supports the development of an "organ on-a-chip" model to study oral cancer and bone invasion at Oregon Health & Science University. The key products and services to be delivered through this 5-year grant include: (1) systematically manipulating, characterizing, and...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $421,625 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to the Texas A&M Engineering Experiment Station (Tees) to develop advanced tumor microenvironment chips (TME-chips) that incorporate functional blood and lymphatic capillary networks. The objective is to create innovative in-vitro systems that can accurately model oral squamous cell carcinoma (OSCC) tumor microenvironments,...
- This $245,504 Project Grant awarded by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports research to develop new treatment approaches for oral squamous cell carcinoma (OSCC). The project explores targeting the stress-specific functions of the essential DNA replication factor Replication Protein A (RPA) to selectively enhance OSCC treatment responses. Researchers from the University of North Carolina at...
- This $612,048 federal Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121) supports research to investigate the role of the lysyl oxidase propeptide (LOX-PP) in regulating macrophage phenotypes and their impact on oral squamous cell carcinoma (OSCC) tumor suppression. The research aims to characterize the differential effects of wildtype versus variant LOX-PP on macrophage activation,...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $451,000 Project Grant under the Oral Diseases and Disorders Research program (CFDA 93.121) to The Regents of the University of California, San Francisco (UCSF) to develop and characterize metastatic MYB-NFIB fusion adenoid cystic carcinoma (ACC) cell line models. The goal is to better understand the oncogenic function of these gene fusions and identify potential drug targets, as ACC is a rare but deadly salivary...
- The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $317,000 project grant (CFDA No. 93.121 - Oral Diseases and Disorders Research) to Temple University to investigate the role of amplified protein kinases in head and neck squamous cell carcinoma (HNSCC) progression and therapy resistance. The 2-year project aims to test whether the protein kinase TNIK, which is amplified in 20% of HNSCC cases, sustains HNSCC cell proliferation and viability by activating focal...
- This federal Project Grant award in the amount of $469,830.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The grant aims to identify oral bacterial species with anti-cancer properties and evaluate their potential for preventing or treating oral squamous cell carcinoma (OSCC). Specifically, the study will assess the effects of Streptococcus mitis and Haemophilus parainfluenzae on OSCC...
- This Project Grant award of $315,000.00 was provided by the National Institute of Dental and Craniofacial Research (NIDCR), which administers the Oral Diseases and Disorders Research federal grant program (CFDA 93.121). The goal of this 2-year project is to study the role of the TRPC1 protein as a potential therapeutic target for treating oral squamous cell carcinoma (OSCC), a common and deadly type of head and neck cancer. The research will focus on understanding how TRPC1 mediates calcium...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $616,000 Project Grant to the Rowan University School of Osteopathic Medicine. This grant, with a performance period from Aug 1, 2025 to Jul 31, 2029, will support research investigating the use of the Hedgehog signaling pathway inhibitor drug sonidegib as a potential therapeutic strategy for oral squamous cell carcinoma (OSCC). The key...
- The National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), awarded a $219,660 Project Grant to the Regents of the University of Michigan to conduct research on "Intercepting the Evolution of Pro-Tumoral Myeloid Cells During the Initiation of Oral Cancer". This project aims to investigate how myeloid cells in precancerous lesions develop suppressive phenotypes that inhibit anti-tumor immune...
MATERIAL STIFFNESS DIRECTS ORAL CANCER MIGRATION - PROJECT SUMMARY ORAL SQUAMOUS CELL CARCINOMA (OSCC) IS THE SIXTH MOST COMMON EPITHELIAL CANCER WORLDWIDE WITH 50,000 NEW CASES/YEAR IN US. DESPITE BEING LESS FREQUENT, SURVIVAL RATES ARE RELATIVE LOWER. CLINICALLY, OSCC PRESENTS AS A NECROTIC LESION WITH STIFFENED BORDERS; SURGICAL RESECTION REQUIRES SIGNIFICANT TISSUE LOSS UP TO 2 CM SURROUND THE LESION, OWING TO THE FACT THAT THESE TUMORS ARE POORLY MARGINED AND REQUIRE SIGNIFICANT RESECTION TO ENSURE ALL METASTATIC DISEASE IS REMOVED. EVEN WITH AGGRESSIVE SURGICAL APPROACHES, SIGNIFICANT MORBIDITY AND MORTALITY IS ASSOCIATED WITH OSCC, AND THIS DRAMATICALLY REDUCES PATIENT QUALITY OF LIFE. WHILE STIFFENED BORDERS ARE A HALLMARK OF THE DISEASE, IT IS UNCLEAR TO WHAT EXTENT MICROENVIRONMENTAL PROPERTIES, E.G., MECHANICAL CHANGES IN EXTRACELLULAR MATRIX (ECM) STIFFNESS, CONTRIBUTE TO TUMOR PROGRESSION AND INVASION. THE ROLE OF STIFFNESS HAS BEEN WELL ESTABLISHED IN OTHER EPITHELIAL TUMORS, E.G., BREAST, BUT OUR UNDERSTANDING IN OSCC IS RELATIVELY NASCENT; LESS THAN 10 STUDIES HAVE EVEN PERIPHERALLY ADDRESSED THE ISSUE. PRELIMINARY DATA FROM OUR GROUPS IS THE FIRST TO DEMONSTRATE THAT A STIFFER ENVIRONMENT INDUCES EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) OF ORAL EPITHELIAL CELLS AND THAT THEY ADOPT A MORE AGGRESSIVE BEHAVIOR OF INVASIVE OSCC (MATTE ET AL 2019; MOON ET AL 2023). EMT OF THESE ORAL TISSUES MIGHT CONTRIBUTE TO FREQUENT TUMOR RECURRENCE OBSERVED IN PATIENTS WITH EXCESSIVELY STIFF TUMOR MARGINS. SINCE OSCC IS EXCEEDINGLY INVASIVE, LEARNED BEHAVIORS WITHIN THE STIFFENED TUMOR MUST BE REMEMBERED AND RECALLED ONCE IN SOFTER ADJACENT ORAL TISSUES TO FACILITATE THE ESTABLISHMENT OF SECONDARY DISEASE. THUS, WE HYPOTHESIZE THAT TUMOR STIFFNESS INDUCES THE ACQUISITION AND CONSOLIDATION OF MECHANICAL MEMORY, I.E., EMT AND MIGRATION, WHICH CAN BE RECALLED LATER WHEN THE RESULTING OSCC CELLS DISSEMINATE AND CONTRIBUTE TO TUMOR METASTASIS, INVASION, AND RECURRENCE. TO TEST THIS HYPOTHESIS, WE PROPOSE THE FOLLOWING SPECIFIC AIMS: SPECIFIC AIM 1: ELUCIDATE THE MECHANISMS INVOLVED IN MECHANICAL SENSING LEADING TO "MEMORY" ACQUISITION AND RECALL SPECIFIC AIM 2: DETERMINE TO WHAT EXTENT EPIGENETIC CHANGES IN OSCC INDUCE "MEMORY" CONSOLIDATION
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $112.1k | 8/15/25 | ||
| Not listed | $394.9k | 8/4/25 | ||
| Not listed | $392.2k | 7/8/24 |